Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement with Sweden-based Karo Healthcare. According to the new terms, Zuellig will serve as the exclusive commercialization partner for Karo’s over-the-counter (OTC) anti-fungal treatment Lamisil (terbinafine hydrochloride) across key Asian markets, including Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Vietnam. The financial details of the deal have not been disclosed.
Karo Healthcare boasts a comprehensive portfolio of more than 80 different brands spanning OTC and prescription drugs, addressing various disease areas such as skin health, intimate health, digestive health, foot health, wellness, pain relief, cough and cold, and specialty products. Zuellig Pharma’s extensive network across Asia encompasses healthcare professionals and retail pharmacies, providing a robust platform for the commercialization of Karo’s products.
The two companies are no strangers to collaboration, having partnered in 2019 for Zuellig to offer commercial support for Karo’s portfolio in the Philippines, Vietnam, Singapore, and Indonesia. The development of Lamisil under the new agreement will be managed by Zuellig’s commercial division, ZP Therapeutics, signaling a deepening of the partnership and a commitment to expanding access to Karo’s anti-fungal treatment in the region.- Flcube.com
